Phosphatidylinositol 3'-kinase is a critical mediator of interferon-gamma-induced increases in enteric epithelial permeability

J Pharmacol Exp Ther. 2007 Mar;320(3):1013-22. doi: 10.1124/jpet.106.113639. Epub 2006 Dec 18.

Abstract

The epithelial lining of mucosal surfaces acts as a barrier to regulate the entry of antigen and pathogens. Nowhere is this function of the contiguous epithelium more important than in the gut, which is continually exposed to a huge antigenic load and, in the colon, an immense commensal microbiota. We assessed the intracellular signaling events that underlie interferon (IFN) gamma-induced increases in epithelial permeability using monolayers of the human colonic T84 epithelial cell line. Confluent epithelial monolayers on semipermeable supports were treated with IFNgamma (20 ng/ml), and barrier function was assessed 48 h later by measuring transepithelial electrical resistance (TER: reflects passive ion flux), fluxes of (51)Cr-EDTA and horseradish peroxidase (HRP), and transcytosis of noninvasive, nonpathogenic Escherichia coli (strain HB101). Exposure to IFNgamma decreased barrier function as assessed by all four markers. The phosphatidylinositol 3'-kinase (PI-3K) inhibitors, LY294002 [2-(4-morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one hydrochloride] and wortmannin, did not affect baseline permeability characteristics but completely blocked the drop in TER, increased fluxes of (51)Cr-EDTA and HRP, and significantly reduced E. coli transcytosis evoked by IFNgamma. In addition, use of the pan-protein kinase C (PKC) inhibitor, bisindolylmaleimide I (5 muM), but not rottlerin (blocks PKCdelta), partially ameliorated the drop in TER and inhibited increased E. coli transcytosis. Addition of the PI-3K and PKC inhibitors to epithelia 6 h after IFNgamma exposure still prevented the increase in paracellular permeability but not E. coli transcytosis. Thus, IFNgamma-induced increases in epithelial paracellular and transcellular permeability are critically dependent on PI-3K activity, which may represent an epithelial-specific target to treat immune-mediated loss of barrier function.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bacterial Translocation / drug effects*
  • Cell Line
  • Cell Membrane Permeability / drug effects
  • Cell Membrane Permeability / immunology
  • Colon / drug effects
  • Colon / enzymology
  • Colon / immunology
  • Colon / microbiology
  • Enzyme Inhibitors / pharmacology
  • Epithelial Cells / drug effects
  • Epithelial Cells / enzymology
  • Epithelial Cells / immunology
  • Epithelial Cells / microbiology
  • Escherichia coli / physiology
  • Humans
  • Interferon-gamma / immunology
  • Interferon-gamma / pharmacology*
  • Intestinal Absorption / drug effects*
  • Intestinal Absorption / immunology
  • Intestinal Mucosa* / drug effects
  • Intestinal Mucosa* / enzymology
  • Intestinal Mucosa* / immunology
  • Intestinal Mucosa* / microbiology
  • Phosphatidylinositol 3-Kinases / physiology*
  • Phosphoinositide-3 Kinase Inhibitors

Substances

  • Enzyme Inhibitors
  • Phosphoinositide-3 Kinase Inhibitors
  • Interferon-gamma